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A commentary on
A gene-based association method for mapping traits using reference transcriptome data
by Gamazon ER, Wheeler HE, Shah KP, Mozaffari SV, Aquino-Michaels K, Carroll RJ, et al. Nat Genet 
(2015) 47:1091–8. doi: 10.1038/ng.3367
Uncovering and understanding links between gene expression, brain structure and function, and 
behavior may inform precision medicine by identifying more precise strategies to prevent and 
treat disease. Indeed, gene expression regulation mechanisms contribute to disease susceptibility, 
drug response, and the course of many substance-use disorders (1–3). Gamazon et  al. recently 
reported development of an innovative gene-based association method to further understanding 
of gene-expression regulation mechanisms mediating relationships between single nucleotide 
polymorphism (SNP) variations and phenotypic variability of complex traits (4). They developed a 
computational method to utilize publically available gene expression datasets to estimate proportion 
of gene expression influenced by a person’s genetic profile – genetically regulated expression – and to 
correlate this with complex phenotypes under investigation. Their whole-genome tissue-dependent 
prediction models – incorporating information on gene expression regulation from a set of markers 
in large high-resolution transcriptome databases – may be used to uncover mechanisms by which 
SNP-regulated gene expression contributes to disease susceptibility and complex traits. The investi-
gators harnessed the power of large reference transcriptome data sets, such as the Genotype-Tissue 
Expression (GTEx) Project, the Genetic European Variation in Health and Disease (GEUVADIS), 
and Depression Genes and Networks (DGN), among others –  in which both gene variation and 
gene expression levels have been measured – to estimate genetically regulated gene expression of 
SNPs. This information and genome-wide association study (GWAS) data are used to compose 
additive models of gene expression traits trained in reference transcriptome data sets. Thus, this 
novel method – termed PrediXcan – utilizes predictive algorithms to correlate associations between 
estimated genetically regulated gene expression of SNPs and phenotypic traits of interest using regres-
sion methods and non-parametric approaches, as a way to powerfully identify disease risk-mediating 
and trait-associated genes. Interestingly, unlike other gene-based testing methods, PrediXcan allows 
researchers to ascertain the direction of these associations. The authors demonstrated the utility 
of their method by identifying and replicating numerous new candidate associations within a 
previous data set. They explain how such an approach may be used to increase statistical power 
in genetics studies by reducing the multiple-testing penalty, which burdens many single-variant 
analysis approaches. Therefore, this method may afford researchers greater capability of reusing 
GWAS or whole-genome sequence data sets to detect novel trait-associated loci explaining a large 
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portion of disease susceptibility-associated phenotypic variability 
under control of genetically regulated gene expression. Research 
is needed to improve prediction capabilities of this approach 
when applying it to substance-use disorders and other behavioral 
health disorders, and to broaden its utility to map links between 
epigenetics and disease risks or traits.
There are many evidence gaps regarding how gene-regulation 
mechanisms may interact with environmental risk factors to 
contribute to disease susceptibility for substance-use disorders, 
especially during periods of high vulnerability such as brain and 
cognitive developmental windows during youth and adolescence 
(5). Therefore, a high-priority area for future research may be to 
employ this PrediXcan method or similar computational gene-
testing approaches to identify human gene-expression-regulated 
genetic factors and mechanisms mediating risk and resilience 
for drug misuse and substance-use disorders, for instance, dur-
ing brain and cognitive development. As the authors suggest, 
reanalyzing existing publically available GWAS data sets in 
comprehensive biorepositories may increase the efficiency and 
cost-efficiency of elucidating such mechanisms (4). Another 
high-priority precision-medicine area is to determine whether 
and how prediction of expression profiles derived from genetic 
variance may be applied to different patient subgroups (e.g., 
those without substance-use problems, versus those exhibiting 
unhealthy drug or alcohol use but not yet considered to be on 
the severe end of the spectrum, versus those patients with severe 
substance-use disorder).
For this research to include phenotypes informative to both 
addiction-medicine researchers and clinical practice providers, 
rigorous and systematic research first needs to identify patient-
centered health outcomes, which are reliably correlated with clini-
cally meaningful changes in drug use in different populations and 
settings of patients with substance-use disorders. This would be 
particularly helpful given that substance-use disorders are chronic 
conditions often characterized by cycles of use, reduced use, absti-
nence, and relapse to use (6–8). Rigorous systematic research is 
also needed to establish reliable biomarkers for substance abuse, 
which might be used as objective measures for guiding such genet-
ics research to predict risk for developing substance-use disorders, 
response to treatment, and risk for relapse. Thus, science needs to 
establish widely accepted clinically relevant phenotypic endpoints 
and biomarkers, which may help in standardizing data collection 
and enable development of common data elements (CDEs) of 
clinically relevant phenotypic measures across studies. CDEs 
may, in turn, facilitate exchange of data by precisely describing 
semantic characteristics for a discrete piece of data, which will 
be collected, stored, or exchanged during the course of a study. 
CDEs of such measures could be key tools in building scalability in 
which uniform data elements with common semantic character-
istics collected across studies can be incorporated and exchanged 
across networks and systems of networks. These benefits may be 
enhanced when CDEs conform to well-accepted data standards 
and ontologies (9). Thus, development and use of CDEs of clinically 
relevant phenotypic measures may facilitate this line of research 
by improving the efficiency and quality of data collection, as well 
as cross study comparisons, data aggregation, and meta-analyses.
Collectively, the above research initiatives are needed to 
accelerate the capacity to catalog gene expression mechanisms 
by which genetic variations map onto addiction risks and altered 
brain maturation, brain circuit function, and substance-use 
disorder behavioral patterns. Uncovering strong genetic evidence 
for such mechanisms can then be leveraged to develop an evi-
dence-based Research Domain Criteria (RDoC) framework for 
substance-use disorder phenotypes, to complement one already 
established for other psychiatric conditions by the U.S. National 
Institute of Mental Health (NIMH) (10). Developing such RDoCs 
would expedite mechanistic precision-medicine research on 
genetics of substance-use disorders and psychiatric comorbidity 
to inform development of evidence-based approaches to improv-
ing patient-centered care for patients with multiple co-occurring 
psychiatric conditions.
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